Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million Added 151 new integrated projects, including 13 in late-stage and commercial stage Total integrated projects reached 817, one of the largest portfolios of complex biologics Research Services enabled 7 global programs for molecule discovery, eligible to receive ~$140 million in near-term payments Completed 16 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, increased by 9.6% year-on-year to RMB 18,675.4 million, with non-COVID revenue growing by 13.1%[7] - Gross profit rose by 12.1% to RMB 7,650.8 million, resulting in a gross margin of 41.0%[3] - Net profit increased by 10.5% to RMB 3,945.4 million, with a net profit margin of 21.1%[3] - Revenue for the year ended December 31, 2024, was RMB 18,675,371 thousand, an increase of 9.66% from RMB 17,034,255 thousand in 2023[125] - The net profit for the year was RMB 3,945,371 thousand, compared to RMB 3,570,624 thousand in 2023, representing a growth of 10.45%[126] - The adjusted net profit for the year ended December 31, 2024, was RMB 5,396.9 million, up from RMB 4,950.4 million in 2023, reflecting a growth of approximately 9.0%[101] - The adjusted EBITDA for 2024 was RMB 7,999.3 million, compared to RMB 6,993.0 million in 2023, representing a growth of approximately 14.4%[103] Revenue Breakdown - Revenue from North America rose significantly to RMB 10,695.8 million, accounting for 57.3% of total revenue, compared to RMB 8,073.5 million or 47.4% in the previous year[50] - IND pre-service revenue grew by 30.7% to approximately RMB 7,062.2 million, representing 37.8% of total revenue for the year ending December 31, 2024[51] - Revenue from the XDC segment increased to RMB 3,944.0 million, representing 21.1% of total revenue, compared to RMB 1,906.1 million or 11.2% in the previous year[54] - CRDMO services contributed RMB 18,362,739,000 to total revenue in 2024, up from RMB 16,749,791,000 in 2023, reflecting a growth of 9.66%[137] Operational Highlights - The number of ongoing integrated projects reached 817, with 151 new projects added during the reporting period[4] - The company secured 20 external projects through its "Winning Molecules" strategy, including 13 late-stage clinical and commercial production projects[4] - The total value of uncompleted orders as of December 31, 2024, reached USD 18.5 billion, including USD 10.5 billion in service orders and USD 8 billion in potential milestone payments[7] - The company has empowered over 600 IND submissions, with a recent autoimmune disease project completed in just six months, significantly optimizing the development cycle from DNA to IND to nine months[17] - The WuXiaTM platform has delivered over 1,000 cell lines, enabling 150 comprehensive CMC projects annually, making it one of the largest platforms in the industry[18] Strategic Partnerships and Collaborations - The company has established partnerships with the top 20 global pharmaceutical companies and most large pharmaceutical companies in China, expanding its customer base[8] - The company has established strategic collaborations with GSK, Candid Therapeutics, BioNTech, and Medigene to advance new biopharmaceutical technologies, enhancing client trust and driving innovation in biotherapy[16] - The company has established a strategic partnership with Merck for the development of the B cell depletion therapy CN201, showcasing the unique advantages of its CRDMO platform[29] Production and Capacity Expansion - The company has expanded its production services significantly, with 66 late-stage clinical and 21 non-COVID commercialization projects as of the reporting period end[32] - The company has enhanced its production capacity, increasing the total capacity at its Hangzhou facility to 23,000 liters and completing mechanical work at its Suzhou facility, which is expected to reach GMP readiness soon[39] - The company has achieved GMP certification for all three production facilities in Ireland, successfully completing multiple 16,000-liter scale PPQ productions during the reporting period[35] Financial Management and Expenses - Sales and marketing expenses increased by 61.1% from approximately RMB 294.0 million for the year ended December 31, 2023, to approximately RMB 473.6 million for the year ended December 31, 2024, with the percentage of sales and marketing expenses to revenue rising from 1.7% to 2.5%[62] - Administrative expenses grew by 11.9% from approximately RMB 1,495.4 million for the year ended December 31, 2023, to approximately RMB 1,673.5 million for the year ended December 31, 2024, driven by increased employee-related costs and support for global business expansion[63] - Research and development expenses decreased by 2.5% from approximately RMB 785.8 million for the year ended December 31, 2023, to approximately RMB 766.4 million for the year ended December 31, 2024, due to automation and enhanced operational efficiency[64] Shareholder Returns and Dividends - The board of directors did not recommend any final dividend for the year ended December 31, 2024[3] - The company did not declare any dividends for the year ending December 31, 2024, consistent with 2023[12] Sustainability and ESG Initiatives - The company has joined the Science Based Targets initiative (SBTi) and the UN Global Compact, focusing on ESG performance and sustainable practices[38] - The company has received multiple awards for its quality services and commitment to ESG practices, including recognition in the Dow Jones Sustainability Index and MSCI ESG ratings[43] - The company has implemented over 260 improvement projects through its WBS system, achieving increased efficiency, cost savings, and significant contributions to sustainability goals[42] Market Outlook - The global biopharmaceutical market is expected to grow at a double-digit rate in the coming years, driven by the increasing demand for biopharmaceuticals and advancements in biotechnologies such as bispecific antibodies and ADCs[46] - The company anticipates continued growth in demand for outsourcing services from biopharmaceutical and biotechnology companies, aimed at accelerating discovery, development, and production processes[46]

Core Insights - WuXi Biologics has successfully passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities, MFG2 and MFG5, in Wuxi city, indicating strong compliance with global regulatory standards [1][2] - The company has a proven track record, having passed 42 regulatory inspections and received 97 license approvals from various drug administration agencies across multiple regions, including the U.S., Europe, China, Singapore, Japan, and Canada [3] - WuXi Biologics employs over 12,000 skilled employees globally and is currently supporting 817 integrated client projects, with 21 in commercial manufacturing, excluding COVID-related projects [5] Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for the discovery, development, and manufacturing of biologics [4] - The company emphasizes Environmental, Social, and Governance (ESG) responsibilities as a core part of its business strategy, aiming to become a leader in ESG within the biologics CRDMO sector [6]

Core Insights - WuXi Biologics has been awarded a Platinum Medal by EcoVadis for the second consecutive year, recognizing its sustainability efforts [1][2][3] - The company ranks in the top 1% of over 150,000 companies evaluated globally by EcoVadis, reflecting its strong performance across various sustainability criteria [2][3] Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [4][5] - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore [5] Sustainability Commitment - WuXi Biologics emphasizes Environmental, Social, and Governance (ESG) responsibilities as a core part of its business strategy, aiming to lead in the biologics CRDMO sector [6] - The company utilizes next-generation biomanufacturing technologies and clean energy sources to enhance its sustainability practices [6] Recognition and Achievements - WuXi Biologics has received multiple accolades for its sustainability initiatives, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices for two consecutive years [3] - The company is also recognized in the CDP Water Security "A list" and has an "A-" CDP Climate Change score, showcasing its commitment to environmental stewardship [3]

Research Service Overview - Asia Value & Moat Stocks is a research service targeting value investors interested in Asia-listed stocks with significant gaps between price and intrinsic value [1] - The service focuses on deep value balance sheet bargains, such as net cash stocks, net-nets, low P/B stocks, and sum-of-the-parts discounts [1] - It also emphasizes wide moat stocks, including "Magic Formula" stocks, high-quality businesses, hidden champions, and wide moat compounders [1] Investment Focus - The service provides investment ideas primarily for the Hong Kong market, with a broader focus on Asia-listed stocks [1] - It offers monthly updated watch lists for deep value balance sheet bargains and wide moat stocks [1] Author Background - The author specializes in identifying deep value balance sheet bargains and wide moat stocks in the Asian market [1] - The author's research is tailored for value investors seeking opportunities in Asia-listed stocks [1]

Investment Rating - The report maintains a "BUY" rating for WuXi Biologics, with a target price raised from HK$22.88 to HK$24.24, indicating a potential upside of 36.6% from the current price of HK$17.74 [3][8]. Core Insights - WuXi Biologics added 151 new projects in 2024, the highest in its history, with over half from the US, showcasing strong global competitiveness and client trust [1][8]. - The company is set to receive US$140 million in near-term payments from enabling discovery services for 7 global projects in 2024, highlighting lucrative milestone income [1][8]. - The Ireland site is on track to achieve breakeven in 2025, and the company plans to expand its drug substance capacity significantly, with a focus on establishing a comprehensive global production network [1][8]. Financial Summary - Revenue is projected to grow from RMB 17,034 million in FY23A to RMB 20,687 million in FY25E, reflecting a year-on-year growth of 13.4% [2][18]. - Adjusted net profit is expected to increase from RMB 4,739 million in FY24E to RMB 5,358 million in FY25E, representing a growth of 13.0% [2][18]. - The adjusted EPS is forecasted to rise from RMB 1.15 in FY24E to RMB 1.30 in FY25E, with a P/E ratio decreasing from 14.3x in FY24E to 12.7x in FY25E [2][18]. Project Pipeline and Growth - The company’s project pipeline now includes 817 projects, with a significant increase in process performance qualification (PPQ) projects expected to grow by 31% YoY to 101 in 2025 [1][8]. - WuXi Biologics completed 77 PPQ projects in 2024, marking a 26% increase year-on-year, indicating strong momentum for future growth in CMO revenue [1][8]. Overseas Operations - The Ireland biologics facility has shown strong client demand trends, successfully completing multiple 16k-liter PPQ batch productions, supporting profitability targets for 2025 [1][8]. - WuXi Biologics is constructing a new 36k-liter drug substance capacity facility in the US, aiming to expand total drug substance capacity to 491k liters, with approximately 49% located overseas [1][8].

Investment Rating - The report maintains a "Buy" rating for WuXi Biologics, reflecting a positive outlook based on demand recovery and growth potential [4][28]. Core Insights - WuXi Biologics achieved a record addition of 151 new projects in 2024, with over half coming from the United States, indicating strong global competitiveness and client trust [2][3]. - The company expects revenue and adjusted profit (excluding minority interests) to grow by 5%-10% in 2024, with accelerated growth anticipated in 2025 [1][4]. - The unique CRDMO business model continues to drive significant milestone revenue, with $140 million in recent payments expected from seven global projects [3][4]. - The company is expanding its global manufacturing network, with a focus on achieving breakeven at its Ireland site in 2025 and increasing drug substance capacity in the U.S. [3][4]. Financial Summary - Revenue is projected to grow from RMB 18,236 million in FY24E to RMB 20,687 million in FY25E, representing a 13.4% increase [5][12]. - Adjusted net profit is expected to rise from RMB 4,739 million in FY24E to RMB 5,358 million in FY25E, reflecting a 13.0% growth [5][12]. - The adjusted earnings per share (EPS) is forecasted to increase from RMB 1.15 in FY24E to RMB 1.30 in FY25E [5][12]. Target Price Adjustment - The target price has been raised from HKD 22.88 to HKD 24.24 based on a discounted cash flow (DCF) model, with a weighted average cost of capital (WACC) of 9.64% and a terminal growth rate of 2.0% [4][6].

Investment Rating - The report assigns a **Buy** rating to WuXi Biologics (2269 HK) with a target price of HK$26.12, representing a 48% upside from the current price of HK$17.60 [1] - The DCF (WACC: 9.9%) target price of HK$26.12 corresponds to a 2025 P/E ratio of 26x [5] Core Views - WuXi Biologics demonstrates strong competitiveness in the high-end market, with 151 new projects signed in 2024, over half from the US, including 13 Phase III and commercialization projects [3] - The company's technical platforms are leading, with 8 projects generating over $200 million annually, 10 projects over $100 million, and 8 projects over $50 million [4] - WuXi Biologics has a significant global presence, with multiple centers and bases in China, the US, and Europe, capturing 70% market share in CDMO services for Chinese innovative drug overseas projects in 2024 [4] - The company expects accelerated revenue growth in 2025, driven by new project signings in research services (R), shortened delivery times in development (D), and a substantial number of PPQ projects in commercial manufacturing (M) [4] Financial Summary - Revenue is projected to grow from RMB 15,269 million in 2022 to RMB 23,611 million in 2026, with a CAGR of 12% [6] - Gross profit is expected to increase from RMB 6,724 million in 2022 to RMB 9,336 million in 2026 [6] - Net profit attributable to shareholders is forecasted to rise from RMB 4,420 million in 2022 to RMB 4,188 million in 2026, with a CAGR of 7% [6] - EPS is estimated to grow from RMB 1.01 in 2022 to RMB 0.96 in 2026 [6] Operational Highlights - WuXi Biologics completed 16 PPQ projects in 2024, with a success rate exceeding 98%, and expects to complete 24 PPQ projects in 2025 [3] - The company has significantly reduced project timelines, with monoclonal antibody projects in North America taking only 9 months from DNA to IND, and autoimmune projects delivered in 6 months, well ahead of industry standards [3] - The company's digital transformation and geopolitical dynamics are expected to further enhance operational efficiency [4]

Summary of Conference Call Company and Industry - The conference call involved a discussion about a strategic partnership between the company and Merck (摩沙东) regarding a vaccine manufacturing facility in Ireland. The focus is on the biopharmaceutical industry, particularly vaccine production and contract development and manufacturing organization (CDMO) services. Core Points and Arguments 1. **Strategic Shift**: The company emphasized that the collaboration with Merck is a strategic move rather than a response to geopolitical factors. The focus is on streamlining operations and enhancing core business areas, specifically in protein drugs, bispecific antibodies, and antibody-drug conjugates (ADC) [2][4][5]. 2. **Vaccine Production Challenges**: The company highlighted that operating a vaccine facility in Europe has resulted in lower-than-expected returns on investment due to high operational costs, especially compared to their facilities in China [3][6][13]. 3. **Asset Efficiency**: The decision to transfer the Irish facility to Merck is aimed at improving asset efficiency and operational flexibility. The company plans to reinvest the capital into higher-return projects and potentially buy back shares [4][5][12]. 4. **Future Collaborations**: Despite the transfer of the facility, the company intends to maintain and enhance its collaboration with Merck in other areas, indicating a continued partnership in biopharmaceuticals [4][5][12]. 5. **Cost Comparison**: The company noted that the operational costs for vaccine production in Ireland are significantly higher than in China, which affects the overall investment returns. This has led to a strategic reassessment of their overseas operations [6][13][14]. 6. **Global Project Pipeline**: The company is optimistic about its global project pipeline, with expectations of significant revenue from ongoing and upcoming projects, particularly in the ADC and other biopharmaceutical sectors [12][19]. 7. **Geopolitical Considerations**: The management clarified that the decision to divest from the Irish facility is not influenced by geopolitical tensions but rather by internal strategic evaluations and the need for better investment returns [14][21]. Other Important Content 1. **Operational Performance**: The company reassured stakeholders that the operational performance of the Irish facility was satisfactory, and the decision to divest was based on strategic financial considerations rather than operational failures [5][21]. 2. **Future Investments**: The company remains committed to investing in overseas operations, including potential projects in Ireland, Singapore, and the U.S., as long as the investment returns meet their criteria [14][21]. 3. **Market Positioning**: The management expressed confidence in their competitive positioning, particularly in utilizing their Suzhou facility to serve global markets effectively, leveraging cost advantages [8][10][17]. 4. **Revenue Expectations**: The company anticipates that the revenue from its global projects will significantly contribute to its financial performance in the coming years, with specific projections of $1.4 billion from seven global projects [12][19]. This summary encapsulates the key discussions and strategic insights shared during the conference call, reflecting the company's focus on optimizing its operations and enhancing its market position in the biopharmaceutical industry.

Core Insights - WuXi Biologics has entered into an agreement with Candid Therapeutics for the exclusive global rights to a preclinical trispecific T-cell Engager, highlighting the collaboration's potential in advancing T-cell engagers for autoimmune and inflammatory diseases [1][2]. Group 1: Agreement Details - Candid Therapeutics will have exclusive global rights to a trispecific T-cell Engager discovered at WuXi Biologics' WuXiBody™ platform, with WuXi Biologics eligible for an upfront payment and development and sales milestones totaling up to $925 million, along with royalties [2]. - The collaboration is expected to enable WuXi Biologics to receive around USD 140 million in near-term payments and total potential payments exceeding USD 2.3 billion [3]. Group 2: Platform Capabilities - The WuXiBody™ platform has been upgraded to deliver customized multispecific antibodies, addressing the global demand for complex molecules, and can expedite the development process by 6-18 months while significantly reducing manufacturing costs [4]. - The platform allows for the assembly of various mAb sequence pairs into multispecific constructs, which are anticipated to have low immunogenicity risk and longer in vivo half-life [4]. Group 3: Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics discovery, development, and manufacturing [5]. - The company employs over 12,000 skilled employees across multiple countries and supports 742 integrated client projects, including 16 in commercial manufacturing as of June 30, 2024 [6]. Group 4: ESG Commitment - WuXi Biologics emphasizes Environmental, Social, and Governance (ESG) responsibilities as a core part of its business strategy, aiming to become an ESG leader in the biologics CRDMO sector [7].